Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Emyria Ltd ( (AU:EMD) ).
Emyria has secured its first Victorian Empax clinic at the Mornington Peninsula, marking a significant milestone in its East Coast expansion and national clinic platform development. This expansion demonstrates Emyria’s ability to deploy its Empax clinic model consistently across jurisdictions using a capital-light, hospital-integrated framework, and active reimbursement pathways, thereby reducing execution risks and supporting revenue growth as new sites come online.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
More about Emyria Ltd
Emyria Limited is a leader in delivering evidence-based intensive mental-health care. The company focuses on establishing a scalable, reimbursed national clinic platform using a capital-light, hospital-integrated operating model. Emyria is expanding its clinic network across multiple states in Australia, including Western Australia, Queensland, and now Victoria.
Average Trading Volume: 3,248,240
Technical Sentiment Signal: Hold
Current Market Cap: A$41.82M
See more insights into EMD stock on TipRanks’ Stock Analysis page.